Optimal treatment strategies in hormone-responsive early breast cancer: The role of aromatase inhibitors

Onkologie

Volumn 30, Issue 1-2, 2007, Pages 55-64

  Untch, M ^a,c   Jackisch, C ^b  

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b Klinikum Offenbach   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adjuvant therapy; Aromatase inhibitor; Breast cancer, early stage; Hormone receptors

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; PLACEBO; TAMOXIFEN; ZOLEDRONIC ACID;

ARTHRALGIA; BONE ATROPHY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURGERY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY CANCER; ENDOMETRIUM CANCER; FATIGUE; FRACTURE; FRAGILITY FRACTURE; HORMONE RESPONSE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MONOTHERAPY; MUSCULOSKELETAL DISEASE; MYALGIA; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; UTERUS BLEEDING;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PHYSICIAN'S PRACTICE PATTERNS; POSTMENOPAUSE; PRACTICE GUIDELINES;

EID: 33846646913     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098423     Document Type: Review

References (60)

1. Buzdar A, Howell A: Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001;7:2620-2635.
2. Crucitta E, Fornier MN, Locopo N, Silvestris N, Lorusso V, De Lena M: Current status and future potential role of exemestane in the treatment of early and advanced breast cancer. Int J Oncol 2002;20:1283-1288.
3. Campos SM: Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 2004;9:126-136.
4. Bhatnagar AS, Brodie AM, Long BJ, Evans DB, Miller WR: Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol 2001;76:199-202.
5. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20:751-757.
6. Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Folkerd E, Cameron D, Dowsett M: Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer. Proc ASCO 2006;24:18s(abstr 552).
7. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998;83:1142-1152. Erratum in: Cancer 1999;85:1010.
8. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-461.
9. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000;18:1399-1411.
10. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M; Arimidex Writing Committee; Investigators Committee Members: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-2258.
11. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-2606.
12. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-2109.
13. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000;18:3758-3767.
14. Nabholtz JM, Bonneterre J, Buzdar A, Robertson JF, Thurlimann B: Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003;39:1684-1689.
15. Paridaens R, Dirix L, Beex L, Nooij M, Cufer T, Lohrisch C, Biganzoli L, van Hoorebeeck I, Duchateau L, Lobelle JP, Piccart M: Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control. Clin Breast Cancer 2000:S19-21.
16. Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Duchateau L, Hamilton A, Lobelle JP, Piccart M: Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14:1391-1398.
17. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-3816.
18. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M; Letrozole Neo-Adjuvant Breast Cancer Study Group: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527-1532.
19. Smith IE: Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy. J Steroid Biochem Mol Biol 2003;86:289-293.
20. Semiglazov V, Kletsel A, Semiglazov V, Zhiltzova E, Ivanov V, Dashyan G, Bozhok A, Melnikova O, Paltuev R, Berstein L: Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0). J Clin Oncol 2005;11s(abstr 530).
21. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:5108-5116.
22. ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-2139. Erratum in: Lancet 2002;360:1520.
23. ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-1810.
24. ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
25. Breast International Group (BIG) 1-98 Collaborative Group: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757.
26. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P: Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian tamoxifen anastrozole trial. J Clin Oncol 2005;23:5138-5147.
27. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-1092. Erratum in: N Engl J Med 2004;351:2461.
28. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-462.
29. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802.
30. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy: randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-1271.
31. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Meeting highlights: International Expert Consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;161:569-583.
32. Rieber AG, Theriault RL: Aromatase inhibitors in postmenopausal breast cancer patients. J Natl Compr Canc Netw 2005;3:309-314.
33. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005;23:619-629.
34. Mouridsen H, Gershanovich M, Monnier A, Boni C, Chaudri H, Staffler B, Dugan M: Letrozole is superior to tamoxifen as first-line hormonal treatment of postmenopausal women with locally advanced or metastatic breast cancer. Ann Oncol 2000;11:155(abstract 709IN).
35. Paepke S, Jacobs VR, Paepke D, Euler U, Blohmer JU, Warm M, Ohlinger R, Fischer T, Kiechle M, Harbeck N. Critical appraisal of primary systemic endocrine therapy in receptor-positive postmenopausal breast cancer: an update. Onkologie. 2006;29:210-7.
36. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-1467.
37. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
38. Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N: Treatment of lymphnode-negative, oestrogen-receptorpositive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. Lancet 2004;364:858-868.
39. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor positive tumors. J Natl Cancer Inst 1996;88:1529-1542.
40. Fisher B, Dignam J, Bryant J, Wolmark N: Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-690.
41. Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-2746.
42. Coombes RC, Paridaens R, Jassem J, Van de Velde CJ, Delozier T, Jones SE, Hall E, Kilburn LS, Snowdon CF, Bliss JM: First mature analysis of the Intergroup Exemestane Study (IES): A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after 2 to 3 years of tamoxifen. Presentation at the 42nd Annual Meeting of the American Society of Clinical Oncology, 2-6 June 2006, Georgia World Congress Center, Atlanta, GA, USA (abstract LBA527).
43. Jakesz R, Gnant M, Greil R, Tausch C, Samonigg H, Kwasny W, Kubista E, Stierer M, Luschin G, Mittlboeck M: The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. Breast Cancer Res Treat 2005;94 (Suppl 1):(abstract 13). Presentation at the 28th Annual San Antonio Breast Cancer Symposium December 8-11, 2005, San Antonio, TX, USA.
44. Kaufmann M, Rody A: Extended breast cancer treatment with an aromatase inhibitor (letrozole) after tamoxifen: why, who and how long? Eur J Obstet Gynecol Reprod Biol 2006;146-154.
45. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M: Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005;23:7512-7517.
46. Viale G, Regan M, Dell'Orto P, Del Curto B, Braye S, Orosz Z, Brown R, Olszewski WP, Knox F, Oehlschlegel C, Thürlimann B: Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 2005;94(suppl 1):(abstr 44).
47. Coombes RC, Hall E, Snowdon CF, Bliss JM: The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis. Breast Cancer Res Treat 2004;88:S7(abstr 3).
48. Cuzick J, Sasieni P, Howell A: Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 2006;94:460-464.
49. Goss P, Ingle J, Dongsheng T: NCIC CTG MA17: disease free survival according to estrogen receptor and progesterone receptor status of the primary tumor. Eur J Cancer Suppl 2005;3:74(abstr 267).
50. Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE: Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006;99(3):295-300.
51. Goss PE, Ingle JN, Palmer NJ: Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs. placebo) post unblinding. Breast Cancer Res Treat 2005;94(suppl 1):(abstr 16). Presentation at the 28th Annual San Antonio Breast Cancer Symposium December 8-11, 2005, San Antonio, TX, USA.
52. Arimidex Prescribing Information: www.arimidex.com. Accessed 2 May 2006.
53. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF: Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:937-947.
54. Herrington DM, Klein KP: Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues 2001;11:95-102.
55. Framingham Heart Study: www.nhlbi.nih.gov/about/framingham/index. html. Accessed 13 July 2006.
56. Rosano GM, Vitale C, Silvestri A, Fini M: Hormone replacement therapy and cardioprotection: the end of the tale? Ann N Y Acad Sci 2003;997:351-357.
57. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S: Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84.
58. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057. Erratum in: J Clin Oncol 2004;22:1351.
59. Brufsky A, Harker G, Beck T, Carroll R, Tan-Chui E, Seidler C, Lacerna L, Thomas E, Perez E: Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): 12 mos BMD results of the Z-FAST trial. J Clin Oncol 2005;23:12s(abstr 533).
60. Gnant M, Jakesz R, Mlineritsch B, Luschin-Ebengreuth G, Schmid M, Menzel C, Kubista E, Samonigg H, Hausmaninger H, the ABCSG, Austrian Breast and Colorectal Cancer Study Group: Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen - bone density subprotocol results of a randomized multicenter trial (ABCSG-12). Breast Cancer Res Treat 2004;88:S8 (abstr 6).